Amylyx Prices Upsized $500 Million Stock Offering Following Positive Avexitide Data
Amylyx Pharmaceuticals priced an upsized public offering of 14.09 million shares at $35.50 per share, raising roughly $500.2 million in gross proceeds (approximately $471.7 million net, and up to $542.5 million if the underwriters’…
